Cargando…
The Limitless Future of RNA Therapeutics
Recent advances in the generation, purification and cellular delivery of RNA have enabled development of RNA-based therapeutics for a broad array of applications. RNA therapeutics comprise a rapidly expanding category of drugs that will change the standard of care for many diseases and actualize per...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8012680/ https://www.ncbi.nlm.nih.gov/pubmed/33816449 http://dx.doi.org/10.3389/fbioe.2021.628137 |
_version_ | 1783673415914225664 |
---|---|
author | Damase, Tulsi Ram Sukhovershin, Roman Boada, Christian Taraballi, Francesca Pettigrew, Roderic I. Cooke, John P. |
author_facet | Damase, Tulsi Ram Sukhovershin, Roman Boada, Christian Taraballi, Francesca Pettigrew, Roderic I. Cooke, John P. |
author_sort | Damase, Tulsi Ram |
collection | PubMed |
description | Recent advances in the generation, purification and cellular delivery of RNA have enabled development of RNA-based therapeutics for a broad array of applications. RNA therapeutics comprise a rapidly expanding category of drugs that will change the standard of care for many diseases and actualize personalized medicine. These drugs are cost effective, relatively simple to manufacture, and can target previously undruggable pathways. It is a disruptive therapeutic technology, as small biotech startups, as well as academic groups, can rapidly develop new and personalized RNA constructs. In this review we discuss general concepts of different classes of RNA-based therapeutics, including antisense oligonucleotides, aptamers, small interfering RNAs, microRNAs, and messenger RNA. Furthermore, we provide an overview of the RNA-based therapies that are currently being evaluated in clinical trials or have already received regulatory approval. The challenges and advantages associated with use of RNA-based drugs are also discussed along with various approaches for RNA delivery. In addition, we introduce a new concept of hospital-based RNA therapeutics and share our experience with establishing such a platform at Houston Methodist Hospital. |
format | Online Article Text |
id | pubmed-8012680 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-80126802021-04-02 The Limitless Future of RNA Therapeutics Damase, Tulsi Ram Sukhovershin, Roman Boada, Christian Taraballi, Francesca Pettigrew, Roderic I. Cooke, John P. Front Bioeng Biotechnol Bioengineering and Biotechnology Recent advances in the generation, purification and cellular delivery of RNA have enabled development of RNA-based therapeutics for a broad array of applications. RNA therapeutics comprise a rapidly expanding category of drugs that will change the standard of care for many diseases and actualize personalized medicine. These drugs are cost effective, relatively simple to manufacture, and can target previously undruggable pathways. It is a disruptive therapeutic technology, as small biotech startups, as well as academic groups, can rapidly develop new and personalized RNA constructs. In this review we discuss general concepts of different classes of RNA-based therapeutics, including antisense oligonucleotides, aptamers, small interfering RNAs, microRNAs, and messenger RNA. Furthermore, we provide an overview of the RNA-based therapies that are currently being evaluated in clinical trials or have already received regulatory approval. The challenges and advantages associated with use of RNA-based drugs are also discussed along with various approaches for RNA delivery. In addition, we introduce a new concept of hospital-based RNA therapeutics and share our experience with establishing such a platform at Houston Methodist Hospital. Frontiers Media S.A. 2021-03-18 /pmc/articles/PMC8012680/ /pubmed/33816449 http://dx.doi.org/10.3389/fbioe.2021.628137 Text en Copyright © 2021 Damase, Sukhovershin, Boada, Taraballi, Pettigrew and Cooke. http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Bioengineering and Biotechnology Damase, Tulsi Ram Sukhovershin, Roman Boada, Christian Taraballi, Francesca Pettigrew, Roderic I. Cooke, John P. The Limitless Future of RNA Therapeutics |
title | The Limitless Future of RNA Therapeutics |
title_full | The Limitless Future of RNA Therapeutics |
title_fullStr | The Limitless Future of RNA Therapeutics |
title_full_unstemmed | The Limitless Future of RNA Therapeutics |
title_short | The Limitless Future of RNA Therapeutics |
title_sort | limitless future of rna therapeutics |
topic | Bioengineering and Biotechnology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8012680/ https://www.ncbi.nlm.nih.gov/pubmed/33816449 http://dx.doi.org/10.3389/fbioe.2021.628137 |
work_keys_str_mv | AT damasetulsiram thelimitlessfutureofrnatherapeutics AT sukhovershinroman thelimitlessfutureofrnatherapeutics AT boadachristian thelimitlessfutureofrnatherapeutics AT taraballifrancesca thelimitlessfutureofrnatherapeutics AT pettigrewroderici thelimitlessfutureofrnatherapeutics AT cookejohnp thelimitlessfutureofrnatherapeutics AT damasetulsiram limitlessfutureofrnatherapeutics AT sukhovershinroman limitlessfutureofrnatherapeutics AT boadachristian limitlessfutureofrnatherapeutics AT taraballifrancesca limitlessfutureofrnatherapeutics AT pettigrewroderici limitlessfutureofrnatherapeutics AT cookejohnp limitlessfutureofrnatherapeutics |